Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

Your browser does not seem to support iframes. <a href="https://flowpaper.com/flipbook/?pdf=https://www.liftt.com/wp-content/uploads/2024/04/Press_release-Evergreen-en.pdf?wp-hosted=1" target="_blank">Click here to read this PDF</a>.

Created using FlowPaper Flipbook Maker ↗

LIFTT Venture Capital Italia2024-04-17T10:21:19+02:0017 April 2024|

FIND OUT MORE

Media Centre
Investor Relations
Careers Centre
Contact

HEADQUARTER

OGR Tech
Corso Castelfidardo 22
10138 Torino TO

INFORMAZIONI

VAT n. 12013790014

Shared Capital
€ 100.835.954,00 authorised,
€ 43.482.552,00 paid,
€ 40.000.000,00 as per last statutory financial statements.

LIFTT S.p.A. adopts an Organization, Management and Control Model in line with the provisions of Legislative Decree 231/2001, and the Code of Ethics as completing part of the Model.

This site uses its own cookies to ensure a better experience on the site. By continuing to browse you agree to their use.
More information, including directions on how to remove cookies and refuse their use. Accetta Rifiuta

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

Share

FIND OUT MORE

HEADQUARTER

INFORMAZIONI

© Copyright 2019 – 2024 | All Rights Reserved